Skin gel for early-stage mycosis fungoides
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a gel form of a drug called duvelisib that you apply directly to skin lesions. It is for people with early-stage mycosis fungoides and may help control the patches without needing whole-body treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage mycosis fungoides (stage IA, IB, or IIA)
- You have 3 to 5 active skin lesions (patches or spots) that can be treated with a gel, but not on your face, neck, or certain other areas
- You have not used certain skin treatments (like steroid creams or nitrogen mustard) on the affected areas for at least 2 weeks before starting
- You have not had whole-body treatments (like steroid pills, light therapy, or chemotherapy) for mycosis fungoides in the last 3 weeks
- You have not taken a type of medicine called a PI3K inhibitor in the last 60 days
- You have not had electron beam radiation therapy in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial tests a spray solution applied to skin lesions caused by mycosis fungoides, a type of cutaneous T cell lymphoma. It aims to see how the spray affects bacteria on the skin and whether it helps the lesions.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a low-dose radiation treatment to the skin for early-stage mycosis fungoides, a type of lymphoma that affects the skin. The goal is to see if this treatment can help eliminate the cancer cells.
This study tests a cream called benvitimod to see if it helps treat a type of skin lymphoma (mycosis fungoides). It may help control skin symptoms with less harsh side effects than other treatments.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.